INTRACOASTAL CAPITAL Amends Phio Pharma Stake (SC 13G/A)

TL;DR

**Big investor INTRACOASTAL CAPITAL updated their stake in Phio Pharma; watch for details on their new ownership percentage.**

AI Summary

INTRACOASTAL CAPITAL, LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, filed an Amendment No. 4 to their Schedule 13G on February 6, 2024, for Phio Pharmaceuticals Corp. This filing indicates a change in their beneficial ownership of Phio's Common Stock as of December 31, 2023. While the specific percentage or number of shares wasn't detailed in the provided text, the amendment suggests a material change in their holdings, which is important for investors to track as it can signal a shift in confidence from significant shareholders.

Why It Matters

Changes in significant shareholder positions can influence stock price and signal confidence (or lack thereof) in the company's future prospects, affecting current and potential investors.

Risk Assessment

Risk Level: medium — Without the specific change in ownership percentage, the impact is uncertain, but any significant shift by a major holder carries potential risk or opportunity.

Analyst Insight

Investors should monitor subsequent filings or company disclosures to determine the exact change in beneficial ownership by INTRACOASTAL CAPITAL, LLC, as this could signal a shift in institutional confidence in Phio Pharmaceuticals Corp. and potentially impact its stock price.

Key Numbers

• 71880W402 — CUSIP Number (identifies Phio Pharmaceuticals Corp.'s Common Stock)
• December 31, 2023 — Date of Event (the date that triggered the filing requirement)
• February 6, 2024 — Filing Date (the date the SC 13G/A was filed with the SEC)
• Amendment No. 4 — Filing Amendment (indicates this is an update to a previously filed Schedule 13G)
• $0.0001 — par value per share (the stated par value of Phio Pharmaceuticals Corp. Common Stock)

Key Players & Entities

• INTRACOASTAL CAPITAL, LLC (company) — reporting person and filer of the SC 13G/A
• Phio Pharmaceuticals Corp. (company) — the subject company whose securities are being reported
• Mitchell P. Kopin (person) — one of the reporting persons and a group member
• Daniel B. Asher (person) — a group member associated with the filing
• 03 Life Sciences (company) — organization name associated with the subject company

Forward-Looking Statements

• The next SC 13G/A filing from INTRACOASTAL CAPITAL, LLC will disclose the exact percentage of beneficial ownership. (INTRACOASTAL CAPITAL, LLC) — medium confidence, target: 2025-02-10
• Phio Pharmaceuticals Corp. stock price will react to the disclosure of the specific ownership percentage once it's made public. (Phio Pharmaceuticals Corp.) — medium confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.0001 — Corp. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

Filing Documents

• ea192888-13ga4intra_phio.htm (SC 13G/A) — 53KB
• 0001213900-24-010340.txt ( ) — 55KB

Ownership

Item 4. Ownership. (a) and (b): As of the close of business on December 31, 2023, each of the Reporting Persons may have been deemed to have beneficial ownership of 891,401 shares of Common Stock, which consisted of (i) 13,539 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“ Intracoastal Warrant 1 ”), (ii) 12,533 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“ Intracoastal Warrant 2 ”) , (iii) 21,458 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“ Intracoastal Warrant 3 ”) , (iv) 248,500 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal (“ Intracoastal Warrant 4 ”) , (v) 218,864 shares of Common Stock issuable upon exercise of a fifth warrant held by Intracoastal (“ Intracoastal Warrant 5 ”) , (vi) 74,608 shares of Common Stock issuable upon exercise of a sixth warrant held by Intracoastal (“ Intracoastal Warrant 6 ”) , (vii) 291,500 shares of Common Stock issuable upon exercise of a seventh warrant held by Intracoastal (“ Intracoastal Warrant 7 ”) and (viii) 10,399 shares of Common Stock issuable upon exercise of an eighth warrant held by Intracoastal (“ Intracoastal Warrant 8 ”) , and all such shares of Common Stock represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 8,031,540 shares of Common Stock outstanding as of December 28, 2023, as reported by the Issuer, plus (2) 13,539 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 12,533 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (4) 21,458 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (5) 248,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4, (6) 218,864 shares of Common Stock issuable upon exercise of Intracoastal Warrant

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. Page 5 of 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 6, 2024 /s/ Mitchell P. Kopin Mitchell P. Kopin /s/ Daniel B. Asher Daniel B. Asher Intracoastal Capital LLC By: /s/ Mitchell P. Kopin Mitchell P. Kopin, Manager Page 6 of 6

View Full Filing

View this SC 13G/A filing on SEC EDGAR